The CYLD-PARP1 feedback loop regulates DNA damage repair and chemosensitivity in breast cancer cells

Miaomiao Zheng1, Shuo Wang1, Kexin Tang1

  • 1Center for Cell Structure and Function, Shandong Provincial Key Laboratory of Animal Resistance Biology, Collaborative Innovation Center of Cell Biology in Universities of Shandong, Department of Biochemistry and Molecular Biology, College of Life Sciences, Shandong Normal University, Jinan, Shandong 250014, China.

Insights

Cylindromatosis (CYLD) deubiquitinates Poly(ADP-ribose) polymerase 1 (PARP1), impacting DNA repair in breast cancer. Targeting this CYLD-PARP1 interaction may enhance chemotherapy efficacy.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • Poly(ADP-ribose) polymerase 1 (PARP1) is vital for DNA repair and genomic stability.
  • Regulatory mechanisms of PARP1, especially deubiquitination, are not fully understood.

Purpose of the Study:

  • To identify deubiquitinases (DUBs) regulating PARP1 activity.
  • To elucidate the role of CYLD in PARP1 regulation and its implications in breast cancer.

Main Methods:

  • Utilized a DUB library binding screen to identify PARP1-interacting DUBs.
  • Investigated the mechanistic interplay between CYLD and PARP1 at DNA lesions.
  • Assessed the impact of CYLD modulation on DNA repair pathways and drug sensitivity in breast cancer cells.

Main Results:

  • Identified cylindromatosis (CYLD) as a deubiquitinase for PARP1 in breast cancer cells.
  • CYLD cleaves K63-linked polyubiquitin chains on PARP1, reducing its activation.
  • PARP1 PARylates CYLD, enhancing its deubiquitinase activity.
  • CYLD depletion increases base excision repair efficiency and confers resistance to alkylating agents.
  • CYLD overexpression sensitizes breast cancer cells to PARP inhibitors (PARPi).

Conclusions:

  • Established a reciprocal regulatory relationship between CYLD and PARP1 in DNA repair.
  • CYLD deubiquitination of PARP1 is a critical mechanism controlling DNA repair efficiency.
  • The CYLD-PARP1 axis represents a potential therapeutic target for breast cancer chemotherapy.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.7K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K